July VQAAB Minutes VQA Advisory Board (VQAAB) Members
|
|
- Mark Matthews
- 5 years ago
- Views:
Transcription
1 To: cc: From: VQA Advisory Board (VQAAB) Members Mike Ussery Joe Fitzgibbon VQA Members Cheryl Jennings Date: 30 July 2010 Subject: VQAAB Conference Call Minutes (call dated 13 July 2010) Attendees: Voting: Bill Meyer (Chair), Walter Scott (IMPAACT), Danielle Jones (HPTN),Susan Fiscus (IMPAACT), Urvi Parikh (MTN), Joan Dragavon (ACTG/HVTN), Belinda Yen-Lieberman (ACTG), Robert Coombs (ACTG/HVTN), Non-voting: Errance Meeks (IMPAACT), Rachana Kshatriya (IMPAACT), Kristi Kaiss (SSS), Ronald Bosch (SDAC), James Bremer (VQA), Heather Sprenger (FSTRF), Brian Harty (NERI), Suzanne Granger (NERI), Paige Etter (HANC), Joe Fitzgibbon (DAIDS), Cheryl Jennings (VQA), Akbar Shahkolahi (SSS), Carrie Wager (NERI) Regrets: Mike Ussery (DAIDS), Don Brambilla (RTI), Meena Doshi (NERI), Agenda: 1. Roll Call 2. Review of June 2010 Conference Call Minutes (Cheryl Jennings) 3. "Canned comments" for HIV reports (Joan Dragavon) 4. Memo to Labs: Specimen Dilution (Cheryl Jennings) 5. Memo to Labs: Manual Abbott Validation Plan (Cheryl Jennings) 6. Proposed changes for HIV RNA PT scoring during the transition from citrated plasma matrix to a SERUM+EDTA matrix (Carrie Wager) 7. Review of New Proficiency Panel Reports (Suzanne Granger) 8. Update on the external HIV RNA 200 copies/ml control results (Suzanne Granger) 9. Change in Laboratory Status Report (Cheryl Jennings) 10. New Items of Interest from the VQA (Jim Bremer/Cheryl Jennings) 11. New Items of Interest from the Committee Members Materials: VQAAB conference call minutes b VQAAB RNA samples _second report VQAAB_DNA185_first report Cumulative Ratings blinded [Proposed changes for HIV RNA PT scoring] (Carrie) Abbott RNA report canned text scenarios-2 VQA_Specimen_Dilution_Plan_02July2010 VQA_Manual_Abbott_Validation_Plan_08July2010 Discussion: Created on 8/13/2010 1:07:00 PM 1 of 5
2 1) Roll Call 2) Review of Conference Call Minutes. The minutes from the June call were submitted to the committee for review. They will be given one week to comment before approved for posting. 3) Canned Comments for HIV Reports. Joan Dragavon presented a third version of the canned text that would be utilized in the LDMS to address different testing scenarios. The purpose of the document is to standardize the LDMS reports to contain all the relevant information/explanations that need to accompany the types of results obtained with the new HIV RNA platforms. This includes the language that will be used for detectable samples with results below the lower detection limit, undetectable samples, diluted samples and samples with results above the upper limit of detection for the assay. A few minor changes were suggested and Joan will finalize the document to include those minor changes. The table will then be given to FSTRF for implementation into the LDMS. 4) Memo: VQA Specimen Dilution Panel A final document was created for the specimen dilution plan that included comments from the last VQAAB conference call. The committee approved (8-0) the document (with a few minor revisions) and agreed that it should be sent to the laboratories for implementation. The plan would also be sent to the cross network Laboratory Focus Group (LFG) for informational purposes. The VQA will finalize and distribute the memo to the LFG and testing laboratories. The VQA will create a spreadsheet for use in capturing the data for the dilution validation as proposed in the memo. The VQA will create a report that will indicate how the data generated by the testing laboratory compared to the preliminary data generated by the VQA. The VQA will share the blinded reports with the VQAAB as they are created for testing laboratories. 5) Memo: Manual Abbott Validation A final document was created for the manual Abbott validation plan that included comments from the last VQAAB conference call. The committee approved (8-0) the document (with a minor revision) and agreed that it should be sent to the laboratories for their records/information. The plan would also be sent to the cross network Laboratory Focus Group (LFG) for informational purposes. The VQA will finalize and distribute the memo to the LFG and testing laboratories. 6) Proposed Changes for HIV RNA PT Scoring Carrie Wager presented the proposed changes for HIV RNA PT scoring during the transition from a citrated plasma matrix to a SERUM+EDT matrix. The current scoring criteria include accuracy, precision, sensitivity, specificity and sample validity. Of these 5 criteria, only sensitivity, accuracy and precision are most susceptible to being affected by a matrix change. The current procedures for scoring include combining four 5 member panels (or a combination of a 20-member prequalification panel plus five-member real-time testing panels) and assessing the five scoring criteria. This combining of data was necessary to permit between run precision analyses and to accumulate sufficient numbers of samples within the analysis to permit reasonable power for these analyses. With the phasing in of a new matrix, there is a change in the n of samples that can be combined for a given analysis which can affect the reliability of that analysis. Therefore, NERI put together a Created on 8/13/2010 1:07:00 PM 2 of 5
3 Created on 8/13/2010 1:07:00 PM 3 of 5 July VQAAB Minutes proposal that would address the issues that could affect VQA HIV RNA PT scoring. These changes are described below. Accuracy accuracy is assessed by comparing the average log10 recovery within a laboratory to the expected log10 recovery. The average laboratory log10 recovery is calculated using data generated by that testing laboratory over the last four rounds. The expected log10 recovery is estimated as the median log10 recovery across all laboratories in which the same kit was used on the panels in question. An algorithm is then applied that generates an accuracy statistic. This statistic is then given a score based on the scoring criteria. In the proposed modification, a weighted average of the differences between the average log10 recovery and the kit-matrix-specific medians will be employed. Simulator studies showed good consistency between these two methods of scoring suggesting the VQA will still be able to adequately assess accuracy as the new matrix is phased into the program. Precision the total assay standard deviation is calculated by combining the inter-assay and intraassay variation and calculating the standard deviation from that sum of variances. As the SER+EDT matrix is phased in there will be changes that occur that will adversely affect these precision analyses. In the first analysis, there will be data from 3 five member panels that were made in citrate and data from 1 five member panel that was made in SER+EDT. This reduces the n of samples available for inter-assay precision studies and there is no inter-assay variance for the SER+EDT data. For the second round of testing, there will be data from 2 five member panels created in citrate and 2 five member panels created in SER+EDT. For the third round of testing, there will be data for 3 five member panels created in SER+EDT and only 1 five-member panel created in citrate. By the fourth round of testing, the data for precision analyses will be a complete set and scoring could proceed normally for precision statistics. Simulations of precision analyses that separated the panels by matrix showed instability with respect to total assay standard deviations. The inter-assay variation component was noted as the main cause of this instability, most likely due to the small sample size in the analysis. Therefore, it was proposed that the VQA continue to monitor and score on intra-assay standard deviations, and to document inter-assay scoring for informational purposes only, until a total of 4 rounds of SER+EDT testing has been completed. Sensitivity sensitivity is assessed by determining the number of negative results obtained from replicates at the limit of detection for the assay in question. This limit of detection varies by kit and is defined as the nominal concentration at which 95% of the assay results are expected to be detectable. Preliminary studies performed by the VQA have shown that the current sensitivity challenge for the UltraSensitive Roche COBAS Amplicor Monitor test were not affected by the switch from citrate to SER+EDT. However, it s not clear how the matrix change may affect the results obtained on samples with a nominal value of 50cp/mL on the Abbott RealTime (AR) or Roche TaqMan (RT) assays. The VQA had started to do evaluations on the performance of this sample created in citrate, but there are insufficient data for samples with this nominal value in SER+EDT. The VQA proposes to continue to score sensitivity in kits that were currently being scored for sensitivity, but to hold off on sensitivity scoring for the new real-time PCR kits (AR and RT). These data will continue to be provided for informational purposes only but will not be included in the proficiency testing scoring. These proposed changes were discussed and approved (8-0) by the VQAAB members. The scoring changes will be implemented in the upcoming analysis of RNA023. The first five samples of that panel will be due 30 July. Scoring will revert back to the original scoring criteria after 4 rounds of
4 testing have been complete which will be the analysis that includes samples through RNA023xx.16-20A which are due 31 January ) Review of New VQA Proficiency Panel Results. Suzanne presented the second report on the analysis on VQA HIV RNA proficiency testing data through samples 06-10A of RNA022. Four data sets from 4 laboratories were included in this analysis. Technical problems were identified in the one data set generated with the Standard Roche Monitor test. An elevated total assay standard deviation was found in this data set. The elevated precision statistic was caused by problems with intra-assay variation. A score of PC was recommended for this data set. No technical problems were noted in the one data set generated with the UltraSensitive Roche Monitor test. A score of C was recommended for this data set. Technical problems were identified in the one data set generated with the Roche TaqMan assay. An elevated total assay SD was found in one data set. The elevated precision statistic was caused by problems with inter-assay variation. A score of P was recommended for this data set. No technical problems were noted in the one data set generated with the BioMerieux EasyQ assay. A score of C was recommended for this data set. One laboratory received a score of NO DATA for both their Standard Roche Monitor assay and their Abbott Realtime data set. No data or request for an exemption were received by the extended due date for either data set. A score of ND is equivalent in point value to a score of P. These data were reviewed and approved (8-0) by the VQAAB committee members. 8) Change in Laboratory Status Report The change in status tracking sheet was circulated to the committee in a blinded manner for review. The scores in the tracking sheet reflect all the analyses done to date. For HIV RNA, there were 6 laboratories that would receive change in status letters as a result of this most recent analysis for RNA: 1 laboratory was REAPPROVED, 1 laboratory was NEWLY APPROVED, 3 laboratories were PROVISIONALLY APPROVED, and 1 laboratory was NOT APPROVED. An un-blinded tracking form will be created and sent to the cross-network leadership for review. Change in status letters be drafted by the VQA, reviewed by Bill Meyer and then sent to the laboratory PI, the affiliated network leadership and DAIDS. 7) Update on External 200cp/mL control The VQA has been trying to compile the data for the VQA 200cp/mL control, but the n of data is too small to do an analysis yet. The problem appears to be that many laboratories are not currently using the new real-time PCR platforms (AR and RT) for routine testing, which means they are only running the VQA control for proficiency testing, which occurs every two months. The VQA is going to work with FSTRF to collect all the extra control data that is available and will send the results of the analysis to this committee for review as soon as it is available. 9) New Items of Interest from the VQA -- The VQA had no new items of interest to discuss. Created on 8/13/2010 1:07:00 PM 4 of 5
5 10) New Items of Interest from the Committee Members Bill Meyer raised the issue of possibly reducing the number of HIV RNA PT challenges per year based on the observation that more laboratories seem to be doing better. He proposed reducing the number of challenges from six to four per year. The committee felt this would require more time for discussion so this will be added to the next month s agenda. However the VQA did want to suggest that any changes in frequency not change until after the new matrix has been fully phased in which would occur after January The next conference call is scheduled for Tuesday, 10 August 2010 at 1:00 PM Eastern. Created on 8/13/2010 1:07:00 PM 5 of 5
Introduction: Table/Figure Descriptions:
Introduction: We have completed the analysis of your HIV RNA Validation Study. The validation plan was designed to verify the installation of an unmodified FDA-approved HIV RNA assay into your laboratory.
More informationVQA HIV DNA Control SOP Version 5.0 HIV DNA Testing 13 March 2012
1. PRINCIPLE 1.1. The Virology Quality Assurance (VQA) Laboratory provides external cell pellet controls for use in the validation of assays that detect HIV proviral DNA. 1.2. HIV seronegative peripheral
More informationVARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD
VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD SOURCES OF VARIATION (RANDOM VS SYSTEMATIC) MAGNITUDE OF EACH SOURCE CONSEQUENCES FOR CONFIDENCE LIMITS AROUND MEASUREMENTS AND CHANGES DATA FROM ROCHE HIV
More informationHIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27
1 The National Laboratory for HIV Reference Services is Accredited to ISO 15189 and ISO 17043 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology
More informationHIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26
1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary
More informationVQA Control SOP Version 4.0 Roche Amplicor HIV-1 DNA Test, v August 2007
1. PRINCIPLE 1.1. The Virology Quality Assurance (VQA) Laboratory provides external cell pellet controls for use in the validation of assays that detect HIV proviral DNA. 1.2. HIV seronegative peripheral
More information2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
More informationNIAID DAIDS FLOW CYTOMETRY LABORATORY CERTIFICATION
January 21, 2010 NIAID DAIDS FLOW CYTOMETRY LABORATORY CERTIFICATION Laboratories performing flow cytometric enumeration of lymphocyte subsets for NIAIDsponsored studies must participate in the NIAID DAIDS
More informationBEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis B (CTDNA11B) Prepared on behalf of QCMD and its Scientific Council October 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis B (CTDNA11B) Prepared on behalf of QCMD and its Scientific Council October 2011 Not to be reproduced or quoted without permission of QCMD. Any
More informationResults of the College of American Pathologists (CAP) Proficiency Program for CMV, EBV, and BKV Viral Load Testing
2009 College of American Pathologists. The College does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The College hereby authorizes
More informationMultilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2011, p. 2854 2858 Vol. 49, No. 8 0095-1137/11/$12.00 doi:10.1128/jcm.00471-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationBEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011 Not to be reproduced or quoted without permission of QCMD.
More informationHOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town
HOPE Follow-Up Algorithm: Unusual Cases Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town MTN-025 Testing Algorithm Screening/Enrollment MTN-025 Testing Algorithm
More informationHepatitis C Virus (RNA)A
Hepatitis C Virus (RNA)A 2012 EQA Programme Final Report QAV994112 (HCVRNA12A) Professor Jacques Izopet Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2012 A UKAS accredited
More informationFollow-up Visit Procedures MTN-009
Follow-up Visit Procedures MTN-009 General Overview MTN-009 follow-up visits are only required for participants who are found to be HIV infected These participants will have a minimum of two follow-up
More informationMTN 015 SPECIMEN REVIEW. Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe
MTN 015 SPECIMEN REVIEW Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe Review of MTN 015 Study MTN 015 is a multi-site observational cohort study whose study population are women who seroconverted
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationCharacterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels
Characterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels Hezhao Ji / Emma R Lee National HIV and Retrovirology Laboratories National Microbiology Laboratory at JC
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Abbott RealTime HIV-1 (m2000sp) Number: PQDx
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Abbott RealTime HIV-1 (m2000sp) Number: PQDx 0145-027-00 Abstract Abbott RealTime HIV-1 (m2000sp) assay with product code 2G31, which
More informationUpdate from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationB19 Virus EQA Programme Final Report QAV (B19DNA14)
B19 Virus 2014 EQA Programme Final Report QAV034116 (B19DNA14) Prof. Hubert GM Niesters Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2014 A UKAS accredited proficiency
More informationChlamydia trachomatis
Chlamydia trachomatis 2012 EQA Programme A Final Report QAB004101 (CTDNA12A) Dr Anton M van Loon Scientific Experts on behalf of QCMD Report authorised by the QCMD Executive in May 2012 A UKAS accredited
More informationComparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms
JCM Accepted Manuscript Posted Online 10 June 2015 J. Clin. Microbiol. doi:10.1128/jcm.00801-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 3 Comparison of Three Different
More informationChlamydia trachomatis
Chlamydia trachomatis 2012 EQA Programme A Final Report QAB004101 (CTDNA12A) Version 2 Dr Anton M van Loon Scientific Experts on behalf of QCMD Report authorised by the QCMD Executive in May 2012 A UKAS
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationCryptosporidium Proficiency Test Program for Laboratories using US EPA Method 1623: Cryptosporidium and Giardia
Cryptosporidium Proficiency Test Program for Laboratories using US EPA Method 1623: Cryptosporidium and Giardia in Water by Filtration/IMS/FA, December 2005 version Preferable Specifications to Establish
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Grgić I., Židovec Lepej S., Vince A., Begovac J. (2010) Increased frequency of viral loads above 100,000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison
More informationVOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory
VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory Review of Sample 2 Testing starts here with rapid test (s). Negative
More informationUnderstanding Quality Control for Infectious Disease Testing. Wayne Dimech ASLM Quality Control Workshop Abuja, Nigeria 9 th December 2018
Understanding Quality Control for Infectious Disease Testing Wayne Dimech ASLM Quality Control Workshop Abuja, Nigeria 9 th December 2018 Disclosure Attendance at ASLM part-sponsored by CDC No personal
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationAffordable tests for HIV drug resistance and HIV viral load in Africa Prof Tobias Rinke de Wit
Affordable tests for HIV drug resistance and HIV viral load in Africa Prof Tobias Rinke de Wit 6 th INTEREST Workshop Mombasa, Kenya, May 8-11, 2012 The roll-out of ART in resource poor settings has followed
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere q HIV-1/2 Detect WHO reference number: PQDx 0226-032-00 Alere q HIV-1/2 Detect with product codes 270110050, 270110010 and 270300001,
More informationHIV Serology Quality Assessment Program Summary for Panel HIVS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationPROFICIENCY TESTING POLICY
Supersedes Prepared by: APPROVALS in this section Approved by: Date: Laboratory Director RECORD OF REVIEWS Date Signature Title Procedural Changes/Review VERSION HISTORY Revision # 0 Section #/Changes
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationCOMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI)
COMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI) Kevin D McCormick; Kerri J Penrose; Rahil Sethi; Jacob Waldman; William Schwarzmann; Uma Chandran;
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationConsolidated Donor Funded Procurement of HIV Diagnostics
Consolidated Donor Funded Procurement of HIV Diagnostics Meeting on HIV Diagnostic Global Demand Forecast Geneva, 9 April 2015 Mercedes Perez Gonzalez Prequalification Team Diagnostics Assessment Department
More informationPractical Aspects of Standardisation for a Global Controls Manufacturer
Practical Aspects of Standardisation for a Global Controls Manufacturer MRSA SoGAT Clinical Diagnostic Meeting NIBSC, UK June 25, 2008 Frank Opdam PhD, AcroMetrix Standardisation A fundamental goal of
More informationAuthor's response to reviews
Author's response to reviews Title: Stable Hepatitis C Virus RNA Detection by RT-PCR During Four Days Storage Authors: Anne-Isabelle de Moreau de Gerbehaye (ng.deradigues@yucom.be) Monique Bodeus (bodeus@mblg.ucl.ac.be)
More informationMTN 009 Laboratory Logistics
MEDICAL RESEARCH COUNCIL OF SA HIV PREVENTION RESEARCH UNIT MTN 009 Laboratory Logistics RASHIKA MAHARAJ HPRU LABORATORY MANAGER Testing Menu Finger stick Blood Samples HIV Rapid Tests* Venous Blood Samples
More informationBNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples
BNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples ASSAY CHARACTERISTICS Method Competitive Enzyme Immunoassay, HRP/TMB. Microtiter plates are coated with a polyclonal
More informationPrior to site activation the following events were lined up
Pardon Gomani CALENDAR OF EVENTS Prior to site activation the following events were lined up October 2008 Operational walk through in JHB 9 to 17 July study specific training Harare 27 August 09 site specific
More informationComparison of Quantitative and Qualitative PCR Assays for Cytomegalovirus DNA in Plasma
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2001, p. 1334 1338 Vol. 39, No. 4 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.4.1334 1338.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationStandardization of Immune Biomarkers: Lessons From the HIV Field
Standardization of Immune Biomarkers: Lessons From the HIV Field Alan Landay, PhD Rush University Medical Center Thomas Denny, MSc Duke University Medical Center and Viral Load Standardization Immunology
More informationDevelopment of a NIST Standard Reference Material for Cytomegalovirus
Development of a NIST Standard Reference Material for Cytomegalovirus Marcia Holden, Ross Haynes, Margaret Kline, John Butler (with help from David Duewer (NIST) and Steve Ellison (LGC)) Group, Biochemical
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx 0244-055-00 OraQuick HCV Rapid Antibody Test Kit with product codes 1001-0270
More informationSection Annual Report Substance Abuse, Addictions and Tobacco Dependence Education
Section Annual Report Substance Abuse, Addictions and Tobacco Dependence Education Submitted by: Margie Arnett, Chair, Loma Linda University School of Dentistry Contact Information: Phone: (909) 558-7283
More informationUse of Viral Load Testing in Managing CMV Infections in SOTR
Use of Viral Load Testing in Managing CMV Infections in SOTR Angela M. Caliendo, MD, PhD, FIDSA Professor and Vice Chair, Medicine Alpert Medical School of Brown University Providence, RI Disclosures Scientific
More informationLaboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.
000000 00000 0000 000 00 0 bdna () 00000 0000 000 00 0 Nuclisens () 000 00 0 000000 00000 0000 000 00 0 Amplicor () Comparison of Amplicor HIV- monitor Test, NucliSens HIV- QT and bdna Versant HIV RNA
More informationHTLV Serology Quality Assessment Program Summary for Panel HTLS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLS425 2015Oct22
More informationAGENDA. Office of the Clerk: (510)
PUBLIC NOTICE AGENDA Community Relations Committee Tuesday, June 26, 2012 7:30 a.m. 8:30 a.m. Location: Kate Creedon Center for Advanced Wound Care 815 Atlantic Avenue, Suite 100 Alameda, CA 94501 DRAFT
More informationHTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19
More informationTools to Monitor HIV Infection in 2013 and Beyond.
Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive
More informationGeneric Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public
More informationU.S. Caucus Chair and Vice Chair
ACI-NA Committee Leadership Average Time Commitment U.S. Caucus Chair and Vice Chair Leadership call Spring Environmental Affairs Committee secretary, chairs and vice chairs of US and Canadian subcommittees
More informationTable 1. Data for standardization of the sodium thiosulfate solution. Trial Number (if needed)
Lab 4 Report Sheet Name Vitamin C Analysis Team No. Date Section Experimental Results Table 1. Data for standardization of the sodium thiosulfate solution Final Volume Initial Volume 1 2 3 4 (if needed)
More informationCMV Diagnostic Strategies: Current and Future
CMV Diagnostic Strategies: Current and Future Tony Mazzulli, MD, FRCPC, FACP Microbiologist-in-Chief Mount Sinai Hospital & University Health Network, Toronto Faculty/Presenter Disclosure Relationships
More informationHIV immunological and virological monitoring tools. Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011
HIV immunological and virological monitoring tools Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011 Monitoring HIV disease progression and treatment When to start ART? CD4 count When
More informationInvestigating Unresolved HIV Status during Endpoint Confirmation. Kristen Cummings MTN Virology CORE
Investigating Unresolved HIV Status during Endpoint Confirmation Kristen Cummings MTN Virology CORE Tuesday, October 29 th, 2013 Outline 1. Process of conducting investigations and resolving HIV status
More informationTechnical Bulletin No. 162
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationHTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28
More informationSCOTTISH DIABETIC RETINOPATHY SCREENING PROGRAMME PROCEDURE FOR SEARCHING FOR NEWLY DIAGNOSED DIABETIC PATIENTS TO INVITE FOR RETINAL SCREENING
PROCEDURE FOR SEARCHING FOR NEWLY DIAGNOSED DIABETIC PATIENTS TO INVITE FOR RETINAL SCREENING VERSION 1.1 REVIEWED BY: DRS COLLABORATIVE SERVICE MANAGERS PREPARED BY: LISA STEELE DATE OF ISSUE: 26/11/2007
More informationPolymer Technology Systems, Inc. CardioChek PA Comparison Study
Polymer Technology Systems, Inc. CardioChek PA Comparison Study Evaluation Protocol: Accuracy Precision Clinical Correlation PTS Panels Lipid Panel Test Strips For Use in Comparisons to a Reference Laboratory
More information(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR
Real-Time (DNA) Real-time Exicycler 96 Rotor-Gene Q/6000 IU Mix1 Mix2 IU/μl IU/μl IU/μl IU/μl IU/μl IPC NTC C 1 Lot# 2 Freeze & thawing 1 MSDS: Material Safety Data Sheets (TaqMan Real-time ' FAM ' BHQ1
More informationQuality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr
Eastern Health Volume 86 Page 001 CIHRT Exhibit P-3595 Page 1 INDICATOR Financial Overtime Hours / FTE Workload Increase - FTE equivalent Workload Quality Indicators - Anatomic Pathology- HSC/STC TOTAL
More informationAccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
More informationAnnotations to the provisional agenda
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Annotations to the provisional agenda 1. Opening of the meeting 1. The Chair of the Technology Executive
More informationSchool Health Advisory Committee (SHAC)
Critical Health Problems (CHP) & Comprehensive Health Education (CHE) Advisory Committee Aka School Health Advisory Committee (SHAC) Tuesday, January 13, 2015 1:30 4:30 Illinois State Board of Education
More informationExternal validation for CD4 and viral load assays: South African Experience
External validation for CD4 and viral load assays: South African Experience W. Stevens University of Witwatersrand and National Health Laboratory Service Methodologies evaluated in South Africa (NHLS/WITS)
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 21 September 2006 EMEA/CHMP/BWP/298390/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON
More informationUpdate: Body Fluid Testing. Fernando San Gil
Update: Body Fluid Testing Fernando San Gil Background Notes - 1 Year Significant moments in IVD 2013 NATA and the TGA publish new validation and registration requirements for in-house IVDs and for in-house
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationINTERNAL QUALITY CONTROL ( Q I C) QC)
EXTERNAL QUALITY ASSESSMENT PROGRAM (EQAP) BIOCHEMISTRY DEPARTMENT R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty TWO COMPLEMENTARY COMPONENETS OF TQM ARE Internal Quality Control (IQC)
More informationWHO recommendations. Diagnostic testing in infants
WHO recommendations Diagnostic testing in infants Recommendations 2- testing in infants Intervention Reco QoE Comment At or around 6 weeks of age is most efficient time at which to perform a viral test
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationWHO Prequalification of In Vitro Diagnostics Programme
WHO Prequalification of In Vitro Diagnostics Programme International HIV/Viral Hepatitis Co-Infection Satellite Meeting 19 July 2014, Melbourne Anita Sands Prequalification Diagnostics Team Department
More information******************************************************************* MINUTES OF SYMMES TOWNSHIP SPECIAL MEETING
******************************************************************* MINUTES OF SYMMES TOWNSHIP SPECIAL MEETING AUGUST 14, 2018 ******************************************************************* The meeting
More informationInterest Group Agenda/Action Form
Interest Group Agenda/Action Form Date: 9/6/2008 Time: 9:00 AM 12:00 Noon Location: Philadelphia, PA Attendees: Dan Free(Chairman), Donn McVeigh, John DiLiberto, Jean Lucey, Norman Steinberg, George Wallace,
More informationfor Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James SoGAT 2009
for Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James Overview Update on the HPV scheme introduced in 2009 MRSA screening
More informationLOGO. Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University & Thai Society of Clinical Pathology
LOGO Improvement of Coagulation Lab Practice in Thailand via Thailand NEQAS for Blood Coagulation : 4-year Experience Nisarat Opartkiattikul MD,PhD Panutsaya Tientadakul, MD. Department of Clinical Pathology,
More informationMinnesota Administrative Uniformity Committee (AUC) Mission Statement, History and Governing Principles. June 2014
Mission Statement, History and Governing Principles 1. Definitions June 2014 For purposes of this document, the following definitions apply: 1.1. "Group purchaser" Group purchaser has the meaning given
More informationMonitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab
Monitoring for Drug Resistance by Genotyping Urvi M Parikh, PhD MTN Virology Core Lab Outline What is Drug Resistance? Genotyping Algorithm Standard vs Sensitive Resistance Testing Sequencing Protocols
More informationOC ACM Executive Committee January 2018 Meeting Agenda and Notes
OC ACM Executive Committee January 2018 Meeting Agenda and Notes Introductions Review and approve prior meeting minutes Treasurer's Report New Meeting Venue & Program Meeting Dates January Program Meeting
More informationMinutes from Meeting of West Michigan Chapter of NARPM Date: January 16, 2014 Start at 12:00pm End at 1:30pm
Date: January 16, 2014 See attendance list of all attendees. Lunch Order and Served Round the Room Introductions-Name, Company, and How long in Property Management Words of inspiration from Jenni Speaker
More informationEvaluation of the new Abbott mplus feature: Impact on clinical laboratory efficiencies with Abbott RealTime HIV-1, HCV, HBV and CT/NG assays
JCM Accepts, published online ahead of print on 2 October 2013 J. Clin. Microbiol. doi:10.1128/jcm.01672-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 Evaluation
More informationDATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.
Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter
More informationMonitoring of HCV RNA. Hepatitis C Requirements of Antiviral Therapy Monitoring
Monitoring of HCV RNA Hepatitis C Requirements of Antiviral Therapy Monitoring Hepatitis C Requirements of Antiviral Therapy Monitoring Author: Ute Hofmann,, Konrad-Zuse-Str. 1, 07745 Jena, Germany Beatrix
More informationAttendance: Fourteen members were on the call. Eleven delegates and three board members (Emily, Sandy, Beth) were in attendance.
Below is the summary of our November Delegate Meeting. Please feel free to reach out to the delegate liaison (delegateliaison@cosa-recovery.org) if you have any questions. Attendance: Fourteen members
More informationHIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Revised
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationWorkgroup Webinar Tuesday, May 26, :00 p.m.
NIDA Strategic Planning Gene x Environment x Development Interactions (GEDI) Co-Chairs: Naimah Weinberg and Jonathan Pollock SPB Coordinator: Michele Rankin Workgroup Webinar Tuesday, May 26, 2015 3:00
More informationSection 9. Laboratory Considerations
Section 9. Laboratory Considerations 9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-012/IPM 010. As transmission of HIV and other infectious
More informationSPBP Advisory Council Meeting Minutes Thursday, January 25, am-12:00pm WebEx Conference Call
SPBP Advisory Council Meeting Minutes Thursday, January 25, 2018 10am-12:00pm WebEx Conference Call Advisory Council Attendees: John Haines, Kathleen Brady, Jerry Coleman, Rebecca Geiser, Margaret Hoffman-Terry,
More informationTSH COMMUNITY ADVISORY COUNCIL MEETING Monday, May 27, 2013 Mabel Crolly Boardroom, Birchmount Campus
TSH COMMUNITY ADVISORY COUNCIL MEETING Monday, May 27, 2013 Mabel Crolly Boardroom, Birchmount Campus MINUTES PRESENT: REGRETS: GUESTS: Paul Rook; Denis Lanoue; Viji Antony; Ranju Bakshi Advani; Odette
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationCMV DNA Quantification Using an Automated Platform for Nucleic Acid Extraction and Real- time PCR Assay Set-up
JCM Accepts, published online ahead of print on 11 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00721-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More information